Trial of controversial Alzheimer’s drug halted after disappointing results

Cassava Sciences said its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Leave a Reply

Your email address will not be published. Required fields are marked *